Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Dasatinib × Plasma cell × Clear all

Phase

Phase 1 5 Phase 2 3 Phase EARLY_PHASE1 1 Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Myeloid 3 Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Lenalidomide 9 Dexamethasone 9 Bortezomib 8 Zoledronic Acid 7 Melphalan 4 ixazomib 3 daratumumab 3 Prednisone 3 Cyclophosphamide 3 tocilizumab 2 pomalidomide 2 carfilzomib 2 Thalidomide 2 Filgrastim 2 Calcium Dobesilate 2 zanubrutinib 1 talquetamab 1 pegylated granulocyte colony-stimulating factor 1 montelukast 1 isatuximab 1 ibrutinib 1 fludarabine phosphate 1 fludarabine 1 exifone 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 apixaban 1 Vaccination 1 Thiotepa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05944783 2025-02-12

BE-Dasatinib

Centro de Atencion e Investigacion Medica

Phase 4 Not yet recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡